Executive Summary

Digital therapeutics (DTx) are an emerging category of evidence-based technologies that could disrupt drug development and disease treatment. DTx products have not hit the mainstream and will need to meet a high standard of clinical validation that separates these solutions from the sea of available digital health tools and apps on the market.

3 KEY QUESTIONS THIS REPORT WILL ANSWER

1. How has the pandemic advanced DTx? 
2. Why should payers, employers, providers, and drug developers want to invest in DTx now?
3. What must happen next for DTx tools to become key components of how diseases are managed and treated?

WHAT’S IN THIS REPORT? How DTx solutions differ from typical digital health products and the opportunity they offer, as well as an analysis of the factors that will define success for DTx companies.

KEY STAT: US physicians are willing to prescribe DTx to patients based on their clinical efficacy.